RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Erupting Bardarbunga Volcano In Iceland Sits On A Massive Magma Hot Spot
- Genetically Modified Stem Cells Kill Brain Tumors
- Researchers Created A Laser Bullet To See What It Would Look Like - And Here It Is
- How Gut Bacteria Ensure A Healthy Brain – and Could Play A Role In Treating Depression
- Ebola's Evolutionary Roots Are Ancient
- ECFA Workshop: Planning For The High Luminosity LHC
- We're Too Late To Prevent 137,000 More Ebola Cases, Says Epidemiology Paper
- "If we had a contest between the USA and UK, perhaps weighted according to population or GDP, which..."
- "Hi Tommaso,I stumbled on this presentation; the plot on slide nr. 4 might be of interest to you..."
- "Hi Dhrou,of course the HL-LHC lumi leveling is different from the LHCb one - a glance at the plot..."
- "Sorry but a ridiculous test made by an anonymous source does not even qualify to be discussed here..."
- "/* Science advances as much by mistakes as by plans. */ Apparently the mainstream physicists are..."
- How to sell a toxic pesticide the smart way–call it organic
- Leftist dystopia? Anti-technology fever animates opposition to GMOs and other ‘disruptive’ technologies
- CDC faced a nearly impossible balancing act with Ebola, and failed
- Why Chobani reversed course, making yoghurt only from milk from cows not fed GMO grain
- Monterey, California, hotbed of anti-GMO activism, home to new GMO corn farm
- Evolution is sometimes messy or even outright ridiculous